Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announces that it has entered into an exclusive agreement with Nudge Therapeutics to acquire the company and their preclinical cyclic AMP-GMP (cGAS) inhibitor compounds. The agreement allows Veralox to continue development of Nudge’s compounds and trigger acquisition of the company upon achievement of downstream milestones. “We are excited because this agreement allows Nudge to utilize the expertise of Veralox to drive our cGAS program towards a clinical candidate,” said Robert Lowery, CEO of Nudge Therapeutics and CEO of Bellbrook Labs.
Read the full article: Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics //
Source: https://www.prnewswire.com/news-releases/veralox-therapeutics-expands-its-pipeline-with-the-exclusive-option-to-acquire-nudge-therapeutics-302347548.html